Stockscreener 앱 받기
8.42
0.60%
0.05
시간 외 거래:
8.50
0.08
+0.95%
전일 마감가:
$8.37
열려 있는:
$8.33
하루 거래량:
898.79K
Relative Volume:
0.50
시가총액:
$2.45B
수익:
$2.68B
순이익/손실:
$-184.45M
주가수익비율:
-12.37
EPS:
-0.6805
순현금흐름:
$229.23M
1주 성능:
+3.57%
1개월 성능:
+13.02%
6개월 성능:
+7.67%
1년 성능:
+24.74%
1일 변동 폭
$8.26
$8.46
1주일 범위
$8.045
$8.46
52주 변동 폭
$6.50
$9.475
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
명칭
Amneal Pharmaceuticals Inc
전화
908-947-3120
주소
400 Crossing Boulevard, 3rd Floor, Bridgewater
AMRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
8.42 | 2.45B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
RGC
Regencell Bioscience Holdings Ltd
|
22.99 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.18 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.25 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.34 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.01 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-06 | 개시 | Goldman | Buy |
| 2025-02-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-09-06 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | 업그레이드 | Goldman | Sell → Buy |
| 2020-12-14 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-12-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-07-27 | 개시 | Goldman | Sell |
| 2020-05-12 | 업그레이드 | Guggenheim | Sell → Neutral |
| 2019-12-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-07 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-21 | 업그레이드 | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-03-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | 다운그레이드 | SunTrust | Buy → Hold |
| 2018-08-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 개시 | Morgan Stanley | Overweight |
| 2018-06-22 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스
Insider Sell: Gautam Patel Sells 94,906 Shares of Amneal Pharmac - GuruFocus
Insider Sell: Gautam Patel Sells 94,906 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus
Parkinson’s Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | AbbVie, Mitsubishi Tanabe Pharma (NeuroDerm), Cerevance, Amneal Pharma, Pharma Two B, Jazz Pharma - Barchart.com
Parkinson's Disease Market to Show Remarkable Growth Trends - openPR.com
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? - Yahoo Finance
Epinephrine Autoinjector Market Size, Share, and Competitive - openPR.com
FDA approves Amneal’s prednisolone acetate eye drops, launch set for Q3 - Investing.com India
Insider Sell: Gautam Patel Sells 56,426 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus
Amneal Pharmaceuticals receives U.S. FDA approval for prednisolone acetate - TipRanks
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension - MarketScreener
Amneal Pharmaceuticals (AMRX) Gains FDA Approval for Eye Drug | AMRX Stock News - GuruFocus
FDA Green Lights Amneal's $201M Generic Eye Drug: Q3 2025 Launch Set for Pred Forte Alternative - Stock Titan
Amneal Recalls Oral Antibiotic Over Contamination Issue - Infectious Disease Advisor
Teva, Amneal rated Buy, Viatris Neutral as Goldman Sachs reviews generics space - MSN
Amneal Pharmaceuticals at Goldman Sachs Conference: Strategic Growth Vision By Investing.com - Investing.com Canada
Amneal Pharmaceuticals at Goldman Sachs Conference: Strategic Growth Vision - Investing.com
Selective Estrogen Receptor Modulators Market Research 2025-2030: Leading Players Shaping the Future of Selective Estrogen Receptor Modulators Industry - GlobeNewswire Inc.
Analysts Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) PT at $11.60 - Defense World
Wellington Management Group LLP Has $586,000 Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Amneal Pharmaceuticals (NASDAQ:AMRX) Coverage Initiated by Analysts at The Goldman Sachs Group - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.52 Million Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris? - Benzinga
Teva stock, Amneal stock, rated Buy at Goldman (TEVA:NYSE) - Seeking Alpha
Amneal recalls oral antibiotic due to bacterial contamination - MSN
AMRX Stock Coverage Initiated with Buy Rating by Goldman Sachs | AMRX Stock News - GuruFocus
Goldman Sachs initiates Amneal Pharmaceuticals stock with neutral rating - Investing.com
Goldman Sachs initiates Amneal Pharmaceuticals stock with neutral rating By Investing.com - Investing.com UK
Two Sigma Advisers LP Sells 32,400 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Amneal Pharmaceuticals at Jefferies Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Amneal Pharmaceuticals Initiates Nationwide Recall of Contaminated Sulfamethoxazole/Trimethoprim Tablets - Insider Monkey
Amneal Pharmaceuticals (AMRX) Recalls Antibiotic Due to Contamination - GuruFocus
Amneal announces recall of oral antibiotic (AMRX:NASDAQ) - Seeking Alpha
Amneal Pharmaceuticals (AMRX) Recalls Contaminated Tablets Due t - GuruFocus
Amneal Recalls Three Lots of Urinary Tract Infection Tablets - marketscreener.com
Wall Street Analysts Believe Amneal (AMRX) Could Rally 54.36%: Here's is How to Trade - sharewise
Amneal Pharmaceutical LLC Issues a Nationwide Recall of Sulfamethoxazole / Trimethoprim Tablets, USP, 400 mg/80 mg Only, Due to Microbial Contamination - US Recall News
Amneal to Participate at Upcoming Investor Conferences in June - GlobeNewswire
Amneal CEO and CFO Set for Exclusive Presentations at Two Major Healthcare Investor Conferences - Stock Titan
Bank of America Corp DE Has $4.41 Million Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
FDA approves Amneal’s DHE migraine/cluster headache autoinjector - MSN
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $716,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Pharyngitis Treatment Market with Antibiotics and Home - openPR.com
3 Reasons Growth Investors Will Love Amneal (AMRX) - Yahoo Finance
Deutsche Bank AG Has $1.06 Million Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Hydroxychloroquine Market to Witness Remarkable Growth with - openPR.com
Insider Sell: Nikita Shah Sells Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus
Migraine Market Enters New Era Following Satsuma Pharmaceuticals' ATZUMI and Amneal Pharmaceuticals' BREKIYA Regulatory Approval | DelveInsight - PR Newswire
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by BNP Paribas Financial Markets - Defense World
Amneal Pharmaceuticals Inc (AMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Amneal Pharmaceuticals Inc 주식 (AMRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Patel Gautam | Director |
Jun 10 '25 |
Sale |
8.02 |
56,426 |
452,537 |
1,704,050 |
| Shah Nikita | Executive Vice President |
May 16 '25 |
Sale |
7.58 |
49,140 |
372,481 |
388,929 |
0.54%
1.34%
자본화:
|
볼륨(24시간):